Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Status:
Terminated
Trial end date:
2012-10-24
Target enrollment:
Participant gender:
Summary
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual
disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL)
patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of
this regimen will be evaluated in addition to toxicity experienced by patients who proceed to
stem cell transplant. Overall length of remission will also be collected.
Phase:
Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium